High Sustained Response Rate for Glecaprevir, Pibrentasvir in HCV

Share this content:
High Sustained Response Rate for Glecaprevir, Pibrentasvir in HCV
High Sustained Response Rate for Glecaprevir, Pibrentasvir in HCV

THURSDAY, Oct. 12, 2017 (HealthDay News) -- For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir results in a high rate of sustained virologic response, according to a study published online Oct. 11 in the New England Journal of Medicine.

Edward Gane, M.D., from Auckland City Hospital in New Zealand, and colleagues conducted a multicenter trial to examine the efficacy and safety of combination treatment with the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults with HCV infection and compensated liver disease with severe renal impairment, dependence on dialysis, or both. Participants had stage 4 or 5 chronic kidney disease. One hundred four patients were enrolled in the trial.

The researchers found that the sustained virologic response rate was 98 percent. During treatment, none of the patients had virologic failure, and none had a virologic relapse after the end of treatment. Pruritus, fatigue, and nausea were reported in at least 10 percent of the patients. Twenty-four percent of the patients reported serious adverse events. Because of adverse events, four patients discontinued the trial treatment prematurely; three of these had sustained virologic response.

"Treatment with glecaprevir and pibrentasvir for 12 weeks resulted in a high rate of sustained virologic response in patients with stage 4 or 5 chronic kidney disease and HCV infection," the authors write.

The study was funded by AbbVie.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Herbal and Dietary Supplements Are Commonly Mislabeled

Herbal and Dietary Supplements Are Commonly Mislabeled

Bodybuilding products have highest mislabeling rate; many mislabeled products tied to liver injury

Alcoholic Cirrhosis Linked to Increased Admissions, Costs

Alcoholic Cirrhosis Linked to Increased Admissions, Costs

Compared with non-alcoholic cirrhosis, excess 30-day readmissions total 29.2 per 100 patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »